Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist determine a tailored therapy for that patient. . . . Helomics’ is building AI-driven predictive models by leveraging a unique database of 150,000 tumor genomic and drug response profiles gathered from over 15 years of clinical testing using its TruTumor platform, access to over 15 years of outcome data from a national network of oncologists, plus a physical biobank of tumor samples that is being sequenced as part of its CancerQuest 2020 initiative (http://ibn.fm/B9mmE) to generate rich genomic profiles.”
To view the full article, visit http://ibn.fm/tokKQ
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other) that contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled with a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
